AMLX - Amylyx Pharmaceuticals Inc
NYSE * Health Care * Biotechnology
$14.29
$-0.09 (-0.63%)
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
AMLX Key Statistics
Market Cap
$1.59B
P/B Ratio
5.21
EPS
$-1.53
Revenue Growth
-1.0%
Employees
136
How AMLX Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
N/A
of 5
Growth Rank
#6
of 6
Size Rank
#6
of 6
Amylyx Pharmaceuticals Inc Company Information
- Headquarters
- Massachusetts; U.S.A
- Website
- amylyx.com
- Sector
- Health Care
- Industry
- Biotechnology